Median values (ranges) of different continuous clinicopathological features for sporadic breast cancers, cancers in patients with BRCA1 or BRCA2 mutations and in patients with breast cancer who are at different risks of hereditary disease, on the basis of family history
| Feature | Sporadic | Intermediate risk | High risk | BRCA1 mutation | BRCA2 mutation | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | Median (range) | n | Median (range) | n | Median (range) | n | Median (range) | n | Median (range) | |
| Age (years) | 579 | 64 (30–87) | 66 | 51 (26–76) | 19 | 47 (31–77) | 22 | 38 (31–57) | 5 | 56 (38–66) |
| Mitotic activity index | 567 | 10 (0–151) | 63 | 7 (0–130) | 19 | 28 (0–104) | 22 | 30 (0–105) | 5 | 11 (4–56) |
| Tumour size (cm) | 554 | 2.0 (0.1–10) | 63 | 2.0 (0.2–8.0) | 17 | 3.2 (1–22) | 17 | 2.0 (0.5–4) | 5 | 1.5 (1–3) |
| Ki67 (%) | 421 | 10 (0–80) | 62 | 10 (1–90) | 18 | 58 (0–100) | 22 | 75 (2–100) | 5 | 20 (10–70) |
| p53 (%) | 419 | 0 (0–100) | 57 | 1 (0–100) | 19 | 5 (0–100) | 22 | 39 (0–100) | 5 | 0 (0–2) |
| Oestrogen receptor (%) | 423 | 80 (0–100) | 62 | 78 (0–100) | 19 | 0 (0–90) | 22 | 0 (0–100) | 5 | 0 (0–90) |
| Progesterone receptor (%) | 420 | 0 (0–100) | 65 | 25 (0–100) | 19 | 0 (0–80) | 22 | 0 (0–90) | 5 | 35 (0–80) |
| p27 (%) | 412 | 30 (0–100) | 0 | – | 14 | 10 (0–90) | 17 | 50 (0–100) | 2 | 28 (5–50) |
| p21 (%) | 459 | 1 (0–65) | 56 | 2 (0–90) | 18 | 2 (0–20) | 20 | 1 (0–80) | 4 | 3 (0–25) |
| Cyclin E (%) | 424 | 0 (0–20) | 59 | 0 (0–50) | 4 | 0 (0–0) | 5 | 0 (0–1) | 3 | 1 (0–1) |
| Cyclin A (%) | 457 | 5 (0–50) | 48 | 5 (1–60) | 19 | 25 (2–50) | 21 | 35 (5–90) | 5 | 10 (2–20) |
| Cyclin D1 (%) | 427 | 1 (0–90) | 59 | 0 (0–60) | 18 | 1 (0–35) | 22 | 0 (0–50) | 5 | 0 (0–80) |